Abstract

This study compared antibody levels in individuals after receiving the second dose of the Sinovac vaccine and the third dose of the Moderna vaccine. Sinovac, developed in China, uses the inactivated virus method, meaning it contains no live virus. In contrast, the Moderna vaccine, created in the United States, is an mRNA vaccine that prompts the immune system to produce spike proteins, leading to antibody production without using a live virus. Conducted on Prodia employees in Yogyakarta, this observational research used a cross-sectional approach to measure antibody titers after vaccination. The results, analyzed using the Wilcoxon signed test, showed a significant difference in COVID-19 antibody levels between the two groups.

There is no Figure or data content available for this article

References

• Susilo A, Rumende CM, Pitoyo CW, Santoso WD, Yulianti M, Herikurniawan H, et al. Coronavirus disease 2019: tinjauan literatur terkini. J Penyakit Dalam Indones. 2020;7(1):45.
• WHO. World Health Organization.. - World Health Organization [Internet]. Vol. 2019, Who. 2021. p. 5. Available from: https://www.who.int/en/news-room/fact-sheets/detail/arsenic
• Hakam. Understanding the importance of covid-19 vaccines [Internet]. Universitas Gadjah Mada. Universitas Gadjah Mada; 2021. Available from: https://impoff.com/importance-of-cleanliness/
• Sari RK. Identifikasi penyebab ketidakpatuhan warga terhadap Penerapan protokol kesehatan 3m di masa pandemi covid-19 (studi kasus pelanggar protokol kesehatan 3m di ciracas jakarta timur). J AKRAB JUARA. 2021;6(1):84–94.
• Kementerian Kesehatan. Buku saku #infovaksin v7.pdf. Kementerian Kesehatan RI Direktorat Jendelral Pencegahan dan Pengendalian Penyakit. 2021.
• Levinson W. Review of medical microbiology and immunology [Internet]. Vol. 1, The effects of brief mindfulness intervention on acute pain experience: An examination of individual difference. New York: The McGraw- Hill Companies, Inc; 2014. 1195–1202 p. Available from: https://gemilang.ukm.my/iii/encore/record/C__Rb1478597__S%28medical%29 f%3Aa__P1%2C25__Orightresult__U__X6__Ks%402000e%402023?lang=eng&suite=def
• Melief CJM, Van Hall T, Arens R, Ossendorp F, Van Der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125(9):3401–12.
• Sinovac. Sinovac announces preliminary results of phase iii trial on sIPV. Sec. 2018.
• (WHO) WHO. Dasar-dasar Keamanan Vaksin: Pelatihan melalui Elektronik. WHO Vaccine Safety Basics. Https://inVaccine-Safety-TrainingOrg/ [Internet]. 2021; Available from: https://
• Nugroho SA, Hidayat IN. Efektivitas dan keamanan vaksin covid-19?: studi refrensi. J Keperawatan Prof [Internet]. 2021;9(2):61–107. Available from: https://doi.org/10.33650/jkp.v9i2.2767
• Rotty IE, Kristanto EG, Sekeon S, Ekawardani N, Liwe HR. Pembentukan antibodi spesifik sars-cov-2 pasca vaksinasi. Vol. 10. 2022. p. 16–22.
• Notoatmodjo Soekijo. Promosi Kesehatan dan Perilaku Kesehatan. Vol. 53, Journal of Chemical Information and Modeling. Jakarta: Rineka Cipta; 2105.
• Sugiyono. Metode Penelitian Kuantitatif, Kualitatif, dan R&D. Bandung: Alfabeta; 2016. 85 p.
• Santoso S. Statistik Parametrik: Konsep dan Aplikasi dengan SPSS Edisi Revisi. Jakarta: Elex Media Komputindo; 2014.
• Halim M. Covid-19 vaccination efficacy and safety literature review. J Immunol Allergy. 2021;3(3):1–19.

How to Cite This

Article Metrics

Download Statistics

Downloads

Download data is not yet available.

Other Statistics

Copyright and Permissions

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Kesehatan (Jurtekkes) means that the author or authors retain the copyright in the paper. Jurtekkes granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by Jurtekkes in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

Jurtekkes journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

Jurtekkes journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

• BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
• SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability